Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J's Levaquin Gains Additional Indications | Contract Pharma

What are you searching for?

Sign in

J&J’s Levaquin Gains Additional Indications

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The FDA has approved use of J&J’s five-day, once-daily regimen of Levaquin 750 mg I.V. and oral, for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).

The approval is based on results from a double-blind, randomized trial involving 1,109 patients with either cUTI or AP, which assessed the efficacy and safety of Levaquin versus ciprofloxacin (Cipro). Clinical success rates were similar in both treatment groups demonstrating the resolution of, or improvement in, urinary symptoms for both Levaquin and Cipro groups.

Ortho-McNeil, Inc., along with Johnson & Johnson PRD, conducted the trial and the safety profile of Levaquin is similar across doses. Levaquin is marketed by Ortho-McNeil, Inc., and PriCara, Unit of Ortho-McNeil.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters